Immunicum begins enrolment in Phase I/II trial of INTUVAX to treat GIST

Swedish-based biopharmaceutical company Immunicum has commenced enrolment in the Phase I/II clinical trial of INTUVAX for the treatment of patients with gastrointestinal stromal tumour (GIST).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news